Navigation Links
Ikaria® To Present at 2011 BIO Business Forum and International Convention
Date:6/21/2011

HAMPTON, N.J., June 21, 2011 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings, today announced that its Chairman and CEO, Daniel Tasse, will present at the 2011 Biotechnology Industry Organization (BIO) Business Forum and International Convention on Tuesday, June 28, 2011 from 2:30 to 2:45 p.m. EDT in the Georgetown Room at the Walter E. Washington Convention Center in Washington, DC.

About Ikaria, Inc.Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings.  Ikaria's therapies are designed to meet the unique and complex medical needs of these critically ill patients. The Company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. Ikaria, alone or through partners, also markets the INOMAX therapy package in Puerto Rico, Canada, Australia, Mexico and Japan. The Company is pursuing a number of new indications for INOMAX. Ikaria's late-stage pipeline also is comprised of LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. The Company also has a number of investigational compounds in development. Ikaria is headquartered in Hampton, NJ, with research facilities in Seattle, WA and Madison, WI, and manufacturing facilities in Po
'/>"/>

SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
4. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
5. Bionovo to Present at Canaccord Adams Global Growth Conference
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
9. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
10. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
11. Cepheid to Webcast Upcoming Financial Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to ... the Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment ... meals come from and how agriculture impacts their daily lives. This unique exhibit also ...
(Date:7/30/2015)... ... , ... The 2015 Market Research Report on the Global Propanol Industry ... Propanol market with a focus on the Chinese situation. Major companies included in the ... Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... DIEGO, Oct. 31 Optimer Pharmaceuticals, Inc. (Nasdaq: ... from fidaxomicin,s North American phase 3 study at the ... America (IDSA) in Philadelphia, PA. , (Logo: ... of the Division of Infectious Diseases, Chair of the ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... today that the Company will host a conference call ... Thursday, November 5, 2009 to discuss its third quarter ... participate in the call, please dial 800-860-2442 (domestic) or ...
... Pa., Oct. 30 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: BJGP ) ("BMP ... , , -- Oppenheimer 20th Annual Healthcare Conference, to ... the Waldorf=Astoria hotel in New York. Management is scheduled, ... 3, and meet with, institutional investors ...
Cached Biology Technology:Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 2Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 3Additional Data From Fidaxomicin's Phase 3 Study for Clostridium Difficile Infection (CDI) Presented at IDSA Annual Meeting 4BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2009 Financial Results on November 5, 2009 2BMP Sunstone Announces November Investor Conference Participation 2
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... Research and Markets ... the "Capacitive Fingerprint Sensors Patent Landscape" ... date, fingerprint sensing technology is the most reliable ... well developed. This patent landscape focuses on fingerprint ... domain of capacitive fingerprint sensors is closely linked ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... decade, Steve Stice has dedicated his research using embryonic ... degenerative diseases and debilitating injuries. His most recent discovery, ... stem cells, could now aid in national security. ... of Georgia animal science professor and Georgia Research Alliance ...
... CHAMPAIGN, Ill. -- By placing quantum dots on ... University of Illinois have demonstrated enhanced fluorescence intensity ... applications include high-brightness,light-emitting diodes, optical switches and personalized, ... a new way, said Brian Cunningham, a professor ...
... have discovered that a specific mutation of the COX2 ... of ovarian cancer, increasing womens susceptibility to developing the ... the findings are confirmed by further studies, it might ... as aspirin and ibuprofen, which are used already for ...
Cached Biology News:New use for stem cells found in war on terrorism 2New use for stem cells found in war on terrorism 3Researchers set new record for brightness of quantum dots 2Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 2Mutation of the COX2 gene can double or treble a woman's risk of ovarian cancer 3
...
... PCR Spots, Oligo Spots and complementary RNA ... microarray experiments. Use for glass array printing ... for reverse transcription, cDNA labeling, hybridization stringency ... Control PCR Spots and Oligo Spots, ...
MOUSE ANTI DUCK IgY LIGHT CHAIN...
MOUSE ANTI S. MUTANS PEPTIDOGLYCAN...
Biology Products: